[Treatment with peri-operative immunotherapy of resectable PCNBs]

For decades, early-stage, resecable, although potentially curable, non-small cell lung cancer (NSCLC) has been marred by unacceptably high recurrence rates. Anti-PD(L)1 immune checkpoint inhibitors have revolutionized the treatment of advanced NSCLC; the recent approvals of these drugs in the perioperative setting will now transform the paradigm therapeutics of localized NSCLC. In this review, we focus on the role of perioperatively administered immune checkpoint inhibitors in resectable NSCLC, synthesizing the results of early clinical trials, and discussing future directions.